Introduction: Chronic breathlessness is a common and distressing symptom of advanced
disease with few effective treatments. Central nervous system mechanisms are important in …

Background: Breathlessness remains a common and distressing symptom in people with
advanced disease with few effective treatment options. Repurposing of existing medicines …

New treatments are required for severe breathlessness in advanced disease. We conducted
a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical …

Background Breathlessness frequently becomes severe among people with respiratory
disease. Mirtazapine, a widely used antidepressant, has shown promise in the modulation of …

Objectives: Review the mechanism of action of mirtazapine. Identify the FDA-approved and
off-label indications for mirtazapine. Summarize the adverse event profile of mirtazapine …

Objective: Mirtazapine is an α2A antagonist and mixed 5-HT2/5-HT3 antagonist that has
been proposed as a potential treatment for obstructive sleep apnea (OSA). A small …

Refractory breathlessness is one of the most common and devastating symptoms of
advanced cardiorespiratory disease, both malignant and nonmalignant. In spite of increased …

Serotonin enhancing drugs, including l-tryptophan and, more recently, fluoxetine and
paroxetine, have been tested as pharmacologic treatments for sleep apnea syndrome …

Context Chronic or refractory breathlessness is common and distressing. To evaluate new
treatments, outcome measures that capture change in patients' experience are needed …

Background With a complex pharmacologic profile, mirtazapine may promote sleep,
stimulate appetite, improve nausea, and reduce pain. Some practitioners working on the …